Dextech Medical AB
Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer. The company's lead candidate, OsteoDex that has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The compa… Read more
Dextech Medical AB (LQ0) - Net Assets
Latest net assets as of September 2025: €24.76 Million EUR
Based on the latest financial reports, Dextech Medical AB (LQ0) has net assets worth €24.76 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€24.25 Million) and total liabilities (€-510.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €24.76 Million |
| % of Total Assets | 102.1% |
| Annual Growth Rate | -13.96% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1.89 |
Dextech Medical AB - Net Assets Trend (2022–2025)
This chart illustrates how Dextech Medical AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Dextech Medical AB (2022–2025)
The table below shows the annual net assets of Dextech Medical AB from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | €24.76 Million | -16.36% |
| 2024-06-30 | €29.61 Million | -13.71% |
| 2023-06-30 | €34.31 Million | -11.74% |
| 2022-06-30 | €38.88 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dextech Medical AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2046693600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €115.94 Million | 468.22% |
| Total Equity | €24.76 Million | 100.00% |
Dextech Medical AB Competitors by Market Cap
The table below lists competitors of Dextech Medical AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AddTech Hub Public Company Limited
BK:ADD
|
$7.07 Million |
|
Focus Dynamics Group Bhd
KLSE:0116
|
$7.07 Million |
|
Vape Holdings Inc
NASDAQ:VAPE
|
$7.08 Million |
|
Aqua Bio Technology ASA
OL:ABTEC
|
$7.08 Million |
|
Bd Multimedia
PA:ALBDM
|
$7.07 Million |
|
GROUP PAREF INH. EO 25
F:G5I
|
$7.07 Million |
|
Sintex Plastics Technology Limited
NSE:SPTL
|
$7.07 Million |
|
486630
KQ:486630
|
$7.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dextech Medical AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 29,607,686 to 24,762,989, a change of -4,844,697 (-16.4%).
- Net loss of 4,844,697 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-4.84 Million | -19.56% |
| Total Change | €- | -16.36% |
Book Value vs Market Value Analysis
This analysis compares Dextech Medical AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.68x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.44x to 0.68x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | €2.10 | €0.92 | x |
| 2023-06-30 | €1.86 | €0.92 | x |
| 2024-06-30 | €1.60 | €0.92 | x |
| 2025-06-30 | €1.34 | €0.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dextech Medical AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.01x
- Recent ROE (-19.56%) is below the historical average (-15.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -13.55% | 0.00% | 0.00x | 1.02x | €-9.16 Million |
| 2023 | -13.38% | 0.00% | 0.00x | 1.02x | €-8.02 Million |
| 2024 | -15.89% | 0.00% | 0.00x | 1.03x | €-7.67 Million |
| 2025 | -19.56% | 0.00% | 0.00x | 1.01x | €-7.32 Million |
Industry Comparison
This section compares Dextech Medical AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dextech Medical AB (LQ0) | €24.76 Million | -13.55% | -0.02x | $7.07 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |